These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Molnupiravir: A lethal mutagenic drug against rapidly mutating severe acute respiratory syndrome coronavirus 2-A narrative review. Masyeni S; Iqhrammullah M; Frediansyah A; Nainu F; Tallei T; Emran TB; Ophinni Y; Dhama K; Harapan H J Med Virol; 2022 Jul; 94(7):3006-3016. PubMed ID: 35315098 [TBL] [Abstract][Full Text] [Related]
3. Molnupiravir: an antiviral drug against COVID-19. Dave B; Shah KC; Chorawala MR; Shah N; Patel P; Patel S; Shah P Arch Virol; 2023 Sep; 168(10):252. PubMed ID: 37710056 [TBL] [Abstract][Full Text] [Related]
5. SARS-CoV-2 RdRp uses NDPs as a substrate and is able to incorporate NHC into RNA from diphosphate form molnupiravir. Wang M; Wu C; Liu N; Zhang F; Dong H; Wang S; Chen M; Jiang X; Zhang K; Gu L Int J Biol Macromol; 2023 Jan; 226():946-955. PubMed ID: 36528144 [TBL] [Abstract][Full Text] [Related]
6. Repurposing Molnupiravir for COVID-19: The Mechanisms of Antiviral Activity. Yip AJW; Low ZY; Chow VTK; Lal SK Viruses; 2022 Jun; 14(6):. PubMed ID: 35746815 [TBL] [Abstract][Full Text] [Related]
7. Molnupiravir; molecular and functional descriptors of mitochondrial safety. Wallace KB; Bjork JA Toxicol Appl Pharmacol; 2022 May; 442():116003. PubMed ID: 35358570 [TBL] [Abstract][Full Text] [Related]
8. The preclinical discovery and development of molnupiravir for the treatment of SARS-CoV-2 (COVID-19). Pagliano P; Sellitto C; Ascione T; Scarpati G; Folliero V; Piazza O; Franci G; Filippelli A; Conti V Expert Opin Drug Discov; 2022 Dec; 17(12):1299-1311. PubMed ID: 36508255 [TBL] [Abstract][Full Text] [Related]
9. Transfer and biotransformation of the COVID-19 prodrug molnupiravir and its metabolite β-D-N4-hydroxycytidine across the blood-placenta barrier. Chang CH; Peng WY; Lee WH; Lin TY; Yang MH; Dalley JW; Tsai TH EBioMedicine; 2023 Sep; 95():104748. PubMed ID: 37544201 [TBL] [Abstract][Full Text] [Related]
10. Molnupiravir and Its Antiviral Activity Against COVID-19. Tian L; Pang Z; Li M; Lou F; An X; Zhu S; Song L; Tong Y; Fan H; Fan J Front Immunol; 2022; 13():855496. PubMed ID: 35444647 [TBL] [Abstract][Full Text] [Related]
11. A computational comparative analysis of the binding mechanism of molnupiravir's active metabolite to RNA-dependent RNA polymerase of wild-type and Delta subvariant AY.4 of SARS-CoV-2. Celik I; Tallei TE J Cell Biochem; 2022 Apr; 123(4):807-818. PubMed ID: 35132671 [TBL] [Abstract][Full Text] [Related]
12. Molnupiravir for the treatment of COVID-19. Santani BG; LeBlanc BW; Thakare RP Drugs Today (Barc); 2022 Jul; 58(7):335-350. PubMed ID: 35851869 [TBL] [Abstract][Full Text] [Related]
14. Transporter modulation of molnupiravir and its metabolite β-D-N4-hydroxycytidine across the blood-brain barrier in a rat. Chang CH; Peng WY; Lee WH; Yang L; Lin TY; Yang MH; Tsai TH Commun Med (Lond); 2023 Oct; 3(1):150. PubMed ID: 37857815 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of N4-hydroxycytidine incorporation into nucleic acids of SARS-CoV-2-infected host cells by direct measurement with liquid chromatography-mass spectrometry. Urbanowicz K; Opielka M; Stegmann KM; Dickmanns A; Dobbelstein M; Peters GJ; Smoleński RT Nucleosides Nucleotides Nucleic Acids; 2024 May; ():1-9. PubMed ID: 38741480 [TBL] [Abstract][Full Text] [Related]
16. Viral polymerase binding and broad-spectrum antiviral activity of molnupiravir against human seasonal coronaviruses. Wang Y; Li P; Solanki K; Li Y; Ma Z; Peppelenbosch MP; Baig MS; Pan Q Virology; 2021 Dec; 564():33-38. PubMed ID: 34619630 [TBL] [Abstract][Full Text] [Related]
18. Molnupiravir: Mechanism of action, clinical, and translational science. Maas BM; Strizki J; Miller RR; Kumar S; Brown M; Johnson MG; Cheng M; De Anda C; Rizk ML; Stone JA Clin Transl Sci; 2024 Feb; 17(2):e13732. PubMed ID: 38593352 [TBL] [Abstract][Full Text] [Related]
19. Human genetic risk of treatment with antiviral nucleoside analog drugs that induce lethal mutagenesis: The special case of molnupiravir. Waters MD; Warren S; Hughes C; Lewis P; Zhang F Environ Mol Mutagen; 2022 Jan; 63(1):37-63. PubMed ID: 35023215 [TBL] [Abstract][Full Text] [Related]